ENDOXPERTS^™

COMPREHENSIVE ENDOTOXIN SERVICES WITH A SPECIAL FOCUS ON LOW ENDOTOXIN RECOVERY (LER)

ENDOXPERTS™ Endotoxin Services by bioMérieux provide routine testing and feasibility studies as well as specialized services for analytical issues such as LER. Our work for leading pharmaceutical companies has resulted in validated methods for LER, fulfilling regulatory requirements. Applying true scientific soundness, we continue our contribution to the deepened knowledge of the LER phenomenon and complex nature of endotoxin.

Request Information

Order Online

Overview
Method
Resources

Demasking Protocol Development:

We are specialized in developing and validating custom demasking protocols. The new methods ENDO-RS^® and ENDOLISA^® combined provide the technological basis for accurate determination of endotoxins in biopharmaceuticals containing surfactants (e.g. polysorbate). The ENDO-RS^® sample preparation can also be applied in combination with conventional BET test methods, such as LAL, which requires an optimization of the interface. As biopharmaceutical formulations differ in concentrations and compositions, for each formulation an optimized protocol is needed. Our demasking service includes method transfer, validation, training and support.

Root-cause Analysis of LER:

In case of a drug product being affected by LER, a thorough investigation of the underlying causes of the phenomenon in the specific drug product is conducted, as well as for sample containers, API formulation and individual excipients.

Endotoxin Hold-Time Studies:

In order to verify the reliability of the used endotoxin assay, we conduct and report time-dependent endotoxin spiking studies with undiluted drug product lots according to regulatory requirements. The drug product lots are spiked with specified endotoxin levels and held for several days, depending on sample, before being assayed. A decline in endotoxin concentration over time is indicative of LER.

Routine Endotoxin Testing & Feasibility Studies:

Routine endotoxin testing as well as feasibility and comparison studies using rFC and conventional methods.

Method Validation:

Method validation services including all of the validation steps required during a product validation and requested by regulatory authorities.

Scientific studies have demonstrated that biologics typically containing protein in high concentrations and non-ionic surfactants such as polysorbate in combination with chelating agents, are likely to change the aggregate state of the analyte endotoxin in such a way that it is no longer accessible for detection with Factor C-based endotoxin tests (LAL and rFC).

Important guidelines and scientific publications on the subject are:

The ENDO-RS^® method developed by Hyglos, a bioMérieux company, is a unique toolbox for sample preparation addressing masking of endotoxin at
the root cause. The method enables complete endotoxin recovery in biopharmaceutical drug formulations affected by Low Endotoxin Recovery (LER).

PDA Technical Report No. 82 on Low Endotoxin Recovery (LER)

Download

Filename: 2019-04-bioMerieux News_Endotoxins_PDA TR 82_ENDO-RS (002).pdf
Size: 220 KB
Format: application/pdf

ENDOXPERTS™ Flyer

Download

Filename: BIOMERIEUX_Flyer_ENDOXPERTS_En_2018.pdf
Size: 1 MB
Format: application/pdf

Revolutionize Your Endotoxin Testing

Embark on a 6-part journey designed to challenge the traditional norms in endotoxin detection.

The Hunt for the Missing Endotoxin

This white paper reviews the causes contributing to low endotoxin recovery (LER), the impact it creates, as well as solutions which can rectify the issues it results in. We also discuss the advantages and disadvantages of developing your de-masking protocols in-house, and how you can use the ENDO-RS® de-masking tool kit to make the process easier from beginning to end. Following this, we outline the pros and cons of outsourcing your de-masking project, what you should look for in a third-party company, and why you can and should trust bioMérieux with your de-masking protocol development.

WHITE PAPER

Adoption of rFC for Bacterial Endotoxin Testing

Both pharmaceutical companies and regulators have the same goal — ensuring continuous supply of safe drugs and therapies. Global pharmaceutical companies depend upon robust global supply chains to fulfil their endotoxin testing requirements to ensure patient safety. rFC is a safe, sustainable endotoxin testing solution that could mitigate many of the adverse trends impacting global supply chain consistency.

WHITEPAPER

Low Endotoxin Recovery Case Studies

This case study discusses the Low Endotoxin Recovery (LER) phenomenon in the drug testing and mitigation approach using the ENDO-RS® kit and ENDOLISA® assay for detecting endotoxin interference.

WHITEPAPER

Waste in Endotoxin Detection Assays: LAL vs rFC

From traditional to alternate endotoxin testing methods used for product release testing, there is an opportunity to waste less reagent and generate cost savings. Given that Limulus Amoebocyte Lysate (LAL) is packaged in vials (2.6 or 5.2mL) and reconstituted as needed, there is inevitable waste compared to using recombinant Factor C (rFC).